347 related articles for article (PubMed ID: 21138954)
21. Pharmacotherapy of triple-negative breast cancer.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
23. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
24. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
Greenberg S; Rugo HS
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
[TBL] [Abstract][Full Text] [Related]
25. Triple-negative breast cancer: role of the androgen receptor.
Gucalp A; Traina TA
Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.
Resetkova E; Reis-Filho JS; Jain RK; Mehta R; Thorat MA; Nakshatri H; Badve S
Breast Cancer Res Treat; 2010 Aug; 123(1):97-108. PubMed ID: 19911270
[TBL] [Abstract][Full Text] [Related]
27. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Perez EA; Patel T; Moreno-Aspitia A
Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
[TBL] [Abstract][Full Text] [Related]
29. Triple-negative breast cancer.
Stockmans G; Deraedt K; Wildiers H; Moerman P; Paridaens R
Curr Opin Oncol; 2008 Nov; 20(6):614-20. PubMed ID: 18841042
[TBL] [Abstract][Full Text] [Related]
30. Mouse models of triple negative [basal-like/claudin low] breast cancer.
Herschkowitz JI; Lubet R
Breast Dis; 2010; 32(1-2):63-71. PubMed ID: 21965308
[TBL] [Abstract][Full Text] [Related]
31. Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
De Laurentiis M; Cianniello D; Caputo R; Stanzione B; Arpino G; Cinieri S; Lorusso V; De Placido S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S80-6. PubMed ID: 21129616
[TBL] [Abstract][Full Text] [Related]
32. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
33. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic strategies for triple-negative breast cancer.
Tan AR; Swain SM
Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
[TBL] [Abstract][Full Text] [Related]
35. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
Petrelli F; Cabiddu M; Ghilardi M; Barni S
Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
[TBL] [Abstract][Full Text] [Related]
36. Promising therapeutic options in triple-negative breast cancer.
Bilici A; Arslan C; Altundag K
J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
[TBL] [Abstract][Full Text] [Related]
37. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
[TBL] [Abstract][Full Text] [Related]
38. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
39. Triple-negative breast cancer: a short review.
Elias AD
Am J Clin Oncol; 2010 Dec; 33(6):637-45. PubMed ID: 20023571
[TBL] [Abstract][Full Text] [Related]
40. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]